Clinical Trial Update: This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose [Phase 1]

View source ↗

Summary

Phase 1 study in COPD patients evaluating how food and age affect the pharmacokinetics of the oral CXCR2 inhibitor AZD5069; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED